| Cover | Jan. 20, 2022 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Jan. 20, 2022 |
| Entity File Number | 001-39676 |
| Entity Registrant Name | INHIBIKASE THERAPEUTICS, INC. |
| Entity Central Index Key | 0001750149 |
| Entity Tax Identification Number | 26-3407249 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 3350 Riverwood Parkway SE |
| Entity Address, Address Line Two | Suite 1900 |
| Entity Address, City or Town | Atlanta |
| Entity Address, State or Province | GA |
| Entity Address, Postal Zip Code | 30339 |
| City Area Code | 678 |
| Local Phone Number | 392-3419 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $0.001 par value |
| Trading Symbol | IKT |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | false |
